When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
IOVA - Iovance Biotherapeutics: Initial Amtagvi Launch In Focus
Iovance Biotherapeutics Inc.
2024-03-25 14:29:08 ET
Summary
Iovance's tumor-infiltrating lymphocyte (TIL) product, Amtagvi, was recently approved by the FDA for the treatment of advanced melanoma patients who have failed a PD-1 blocking antibody.
Initial numbers from the early days of the launch can be considered when trying to project revenues from Amtagvi going forward.
IOVA can improve potential revenues by gaining approval of its TIL therapies like Amtagvi outside of the US and in new indications.
In the short term, however, the focus may be on the current Amtagvi launch, where some success may already be reflected in the price.